EC Number   |
General Information |
Reference |
|---|
   3.4.22.B80 | drug target |
because of the essential roles of SARS-CoV-2 papain-like protease (PLpro) in the viral polyprotein processing and suppression of host immune responses, it is a crucial target for drug discovery against COVID-19 |
763467 |
| 3.4.22.B80 | drug target |
covalent docking plus MD refinement of a representative set of known SARS-CoV inhibitors into OTUB2, OTUB1, and the PLpro from SARS-CoV-2 is used to probe their inhibitor binding and rationalize a deubiquitinase selectivity. It is pointed out that the structural differences in cellular deubiquitinases suggest that these enzymes may be different enough to be selectively targeted |
762789 |
| 3.4.22.B80 | drug target |
important anti-virus drug target protein |
755740 |
| 3.4.22.B80 | drug target |
significant suppression of viral spread and promotion of antiviral immunity can be achieved by inhibition of PLpro, revealing an inspiring strategy for COVID-19 treatment |
763555 |
| 3.4.22.B80 | drug target |
the enzyme is a target for antiviral drug development |
762892 |
| 3.4.22.B80 | drug target |
the enzyme is an attractive drug target because it has multiple essential functions involved in processing viral proteins, including viral genome replication and removal of post-translational ubiquitination modifications |
763146 |
| 3.4.22.B80 | drug target |
the enzyme is an important target for the treatment of COVID-19. Discussion about the dysregulation effects of PLpro on immune system and drugs that have potential inhibitors for SCoV-2 PLpro |
763692 |
| 3.4.22.B80 | drug target |
the enzyme not only plays an essential role in viral replication but also cleaves ubiquitin and ubiquitin-like interferon-stimulated gene 15 protein (ISG15) from host proteins, making it an important target for developing new antiviral drugs. The best potential candidates for potent and selective PLpro inhibitors are selected. A multistep virtual screening workflow is established. Three main drug design programs are utilized, with several, diverse ways of the evaluation of the potential PLpro inhibitors. Potential toxicity of the drug candidates at the early stages of the design is considered. Emphasis is put on the most important structural analog of SARS-CoV-2 PLpro in the human organism - UCH-L1. Other toxicological parameters are roughly estimated. 950 potential SARS-CoV-2 PLpro inhibitors are identified. Among these, 387 are potentially selective, with low predicted affinity toward human UCH-L1. All the 950 potential PLpro inhibitors are worth taking into account for future experimental evaluation. An open-access database containing all of them is prepared |
763159 |
| 3.4.22.B80 | drug target |
the enzyme represents a putative drug target for SCoV2 |
762888 |
| 3.4.22.B80 | metabolism |
the enzyme (PLpro) is an attractive drug target because it plays an essential role in cleavage and maturation of viral polyproteins, assembly of the replicase-transcriptase complex, and disruption of host responses |
763505 |
